Biblio Discovery — Demo Discovery Service

43 results for "Susan Waserman"

Showing 1–20 · 1.53 seconds · RSS

  1. Journal Article

    Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms

    Arman Zereshkian; Susan Waserman

    Allergy, Asthma & Clinical Immunology, Vol. 17 No. 1 · 2021 · English · DOAJ Scopus

    Abstract Background Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to medication. While a relatively rare phenomenon, early identification and discontinuation of the offending agent is pivotal to patient management. To our…

  2. Journal Article

    IgE-mediated food allergy

    Susan Waserman; Philippe Bégin; Wade Watson

    Allergy, Asthma & Clinical Immunology, Vol. 14 No. S2 · 2018 · English · DOAJ Scopus

    Abstract Food allergy is defined as an adverse immunologic response to a food protein. Food-related reactions are associated with a broad range of signs and symptoms that may involve any body system, including the skin, gastrointestinal and respiratory tracts, and cardiovascular system…

  3. Journal Article

    A case of pediatric serum sickness like reaction (SSLR) after a 2-month re-exposure to amoxicillin

    Devyani Bakshi; Xinxin Tang; Susan Waserman

    Allergy, Asthma & Clinical Immunology, Vol. 20 No. 1 · 2024 · English · DOAJ Scopus

    Abstract Background Serum-sickness like reactions (SSLRs) to amoxicillin have been documented in the medical literature. Beta-lactams are important and commonly used medications especially in the pediatric population. Often, SSLRs present within days of and during first exposure/ingestion to the…

  4. Journal Article

    TNF-α Dysregulation in Asthma: Relationship to Ongoing Corticosteroid Therapy

    Susan Waserman; Jerry Dolovich; Mary Conway et al.

    Canadian Respiratory Journal, Vol. 7 No. 3 · 2000 · English · DOAJ Scopus

    BACKGROUND: Tumour necrosis factor-alpha (TNF-α) is a major proinflammatory cytokine that is thought to be important in the pathogenesis of asthma. However, alterations in systemic regulation of this cytokine in asthma have not been examined in the context of corticosteroid therapy.

  5. Journal Article

    A multi-stakeholder perspective on asthma care in Canada: findings from a mixed methods needs assessment in the treatment and management of asthma in adults

    Suzanne Murray; Sara Labbé; Alan Kaplan et al.

    Allergy, Asthma & Clinical Immunology, Vol. 14 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Background Although several aspects of asthma care have been identified as being sub-optimal in Canada, such as patient education, practice guideline adoption, and access to care, there remains a need to determine the extent to which these gaps remain, so as to investigate their underlying…

  6. Journal Article Full text

    Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry

    Armin Abadeh; Sarah Shehadeh; Stephen Betschel et al.

    PLOS ONE, Vol. 18 No. 11 · 2023 · English · PLOS Scopus

    Background: Despite the increasing number of cases of secondary antibody deficiency (SAD) and immunoglobulin (Ig) utilization, there is a paucity of data in the literature on clinical and patient-reported outcomes in this population. Objective: To describe immunoglobulin utilization patterns…

    Also available at: DOAJ, DOAJ

  7. Journal Article

    Peanut allergy: Beyond the oral immunotherapy plateau

    Kelly Bruton; Paul Spill; Derek K. Chu et al.

    Clinical and Translational Allergy, Vol. 11 No. 6 · 2021 · English · DOAJ Scopus

    Abstract Background There are a lack of disease‐modifying treatments for peanut allergy, which is lifelong in most instances. Oral immunotherapy has remained at the forefront of prospective treatments, though its efficacy is consistently undermined by the risk of adverse reactions and meager…

  8. Journal Article

    Immunoglobulin E (IgE)-mediated food allergy

    Philippe Bégin; Susan Waserman; Jennifer L. P. Protudjer et al.

    Allergy, Asthma & Clinical Immunology, Vol. 20 No. S3 · 2024 · English · DOAJ Scopus

    Abstract Food allergy is defined as an adverse immunologic response to a food. Immunoglobulin E (IgE)-mediated reactions to foods are associated with a broad range of signs and symptoms that may involve any of the following body systems: the skin, gastrointestinal tract, respiratory tract, and…

  9. Journal Article

    Immunoglobulin treatment and clinical outcomes: data from the Ontario Immunoglobulin Treatment program multicenter case registry

    Sarah Shehadeh; Stephen Betschel; Donald William Cameron et al.

    Therapeutic Advances in Hematology, Vol. 16 · 2025 · English · DOAJ Scopus

    Background: The therapeutic use of immunoglobulin (IG) is increasing and accounts for the largest expenditure in the Canadian Blood Services budget. However, more granular data on IG utilization is limited. Objective: To describe IG treatment indications, dosing characteristics, and clinical…

  10. Journal Article

    Online food allergy and anaphylaxis education for school personnel is effective and scalable: experience with the allergyaware e-learning portal from 2015 to 2022

    Bhanu Sharma; Stephanie Ayers; Joni Huang et al.

    Allergy, Asthma & Clinical Immunology, Vol. 21 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Background Providing training to school personnel on how to prevent, recognize, and manage anaphylaxis is critical. Asynchronous e-learning (where instructional material is available on-demand) may be well-suited to help with the implementation, scale, and dissemination of this training…

  11. Journal Article

    Summarizing the 2024 immunotherapy manual of the Canadian society of allergy and clinical immunology

    Aria Bruton Joe; George Cai; Samina Nazarali et al.

    Allergy, Asthma & Clinical Immunology, Vol. 22 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Allergen immunotherapy (AIT) is an essential disease-modifying therapy in the field of allergy and clinical immunology. The Immunotherapy Manual of the Canadian Society of Allergy and Clinical Immunology serves as a comprehensive guide for the safe and effective administration of…

  12. Journal Article

    Pathophysiology of bradykinin and histamine mediated angioedema

    Hermenio Lima; Jiayue Zheng; Dennis Wong et al.

    Frontiers in Allergy, Vol. 4 · 2023 · English · DOAJ Scopus

    Angioedema is characterized by swelling localized to the subcutaneous and submucosal tissues. This review provides an overview of angioedema, including the different types, triggers, and underlying pathophysiologic mechanisms. Hereditary and acquired angioedema are caused by dysregulation of the…

  13. Journal Article

    Secondary Immunodeficiency

    Persia Pourshahnazari; Stephen D. Betschel; Vy. H. D. Kim et al.

    Allergy, Asthma & Clinical Immunology, Vol. 20 No. S3 · 2025 · English · DOAJ Scopus

    Abstract The field of medicine is constantly changing and, as healthcare providers, we are fortunate to be practicing in a time when patients are living longer and novel therapeutic options continue to evolve. However, these new advances may be associated with adverse effects that practitioners…

  14. Journal Article

    Omalizumab in patients with severe asthma and persistent sputum eosinophilia

    Manali Mukherjee; Melanie Kjarsgaard; Katherine Radford et al.

    Allergy, Asthma & Clinical Immunology, Vol. 15 No. 1 · 2019 · English · DOAJ Scopus

    Abstract Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not…

  15. Journal Article

    Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada

    Adil Adatia; Jean-Nicolas Boursiquot; Dawn Goodyear et al.

    Allergy, Asthma & Clinical Immunology, Vol. 20 No. 1 · 2024 · English · DOAJ Scopus

    Abstract Background Hereditary angioedema with normal C1-inhibitor function (HAE nC1-INH) and idiopathic angioedema of unknown etiology (AE-UNK) are rare conditions that cause recurrent subcutaneous and submucosal swelling. The characteristics and clinical outcomes of patients with these conditions…

  16. Journal Article

    Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study

    Paul K. Keith; Gina Lacuesta; Dawn Goodyear et al.

    Allergy, Asthma & Clinical Immunology, Vol. 21 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Background Evidence linking hereditary angioedema (HAE) to the potential association of developing other comorbidities, and how it is affected by HAE treatment is needed. The objective of this study is to identify comorbidities and measure the prevalence in HAE patients, compared to the…